Clinical Trials · NCT05413369
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 582
- Start date
- Jul 2022
- Locations
- 60 sites, China
- Primary endpoint
- Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis